X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Torrent Pharma with Lupin Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TORRENT PHARMA vs LUPIN - Comparison Results

TORRENT PHARMA    Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

LUPIN 
   Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    TORRENT PHARMA LUPIN TORRENT PHARMA/
LUPIN
 
P/E (TTM) x 38.8 40.6 95.5% View Chart
P/BV x 6.8 2.5 273.7% View Chart
Dividend Yield % 0.7 0.7 112.7%  

Financials

 TORRENT PHARMA   LUPIN
EQUITY SHARE DATA
    TORRENT PHARMA
Mar-18
LUPIN
Mar-18
TORRENT PHARMA/
LUPIN
5-Yr Chart
Click to enlarge
High Rs1,5501,465 105.8%   
Low Rs1,144727 157.3%   
Sales per share (Unadj.) Rs354.7349.6 101.5%  
Earnings per share (Unadj.) Rs40.15.6 721.0%  
Cash flow per share (Unadj.) Rs64.229.6 217.1%  
Dividends per share (Unadj.) Rs14.005.00 280.0%  
Dividend yield (eoy) %1.00.5 227.9%  
Book value per share (Unadj.) Rs273.1300.3 91.0%  
Shares outstanding (eoy) m169.22452.08 37.4%   
Bonus/Rights/Conversions -ESOPS-  
Price / Sales ratio x3.83.1 121.1%   
Avg P/E ratio x33.6197.2 17.0%  
P/CF ratio (eoy) x21.037.1 56.6%  
Price / Book Value ratio x4.93.6 135.1%  
Dividend payout %34.990.0 38.8%   
Avg Mkt Cap Rs m227,897495,502 46.0%   
No. of employees `00014.717.0 86.3%   
Total wages/salary Rs m11,35328,647 39.6%   
Avg. sales/employee Rs Th4,083.09,273.6 44.0%   
Avg. wages/employee Rs Th772.31,681.0 45.9%   
Avg. net profit/employee Rs Th461.3147.4 312.9%   
INCOME DATA
Net Sales Rs m60,021158,042 38.0%  
Other income Rs m2,9881,504 198.8%   
Total revenues Rs m63,009159,545 39.5%   
Gross profit Rs m13,49331,475 42.9%  
Depreciation Rs m4,08610,859 37.6%   
Interest Rs m3,0852,044 151.0%   
Profit before tax Rs m9,31020,076 46.4%   
Minority Interest Rs m0-71 0.0%   
Prior Period Items Rs m035 0.0%   
Extraordinary Inc (Exp) Rs m0-14,644 0.0%   
Tax Rs m2,5292,885 87.7%   
Profit after tax Rs m6,7812,513 269.9%  
Gross profit margin %22.519.9 112.9%  
Effective tax rate %27.214.4 189.0%   
Net profit margin %11.31.6 710.7%  
BALANCE SHEET DATA
Current assets Rs m52,623122,095 43.1%   
Current liabilities Rs m52,02250,956 102.1%   
Net working cap to sales %1.045.0 2.2%  
Current ratio x1.02.4 42.2%  
Inventory Days Days12085 141.4%  
Debtors Days Days76120 63.6%  
Net fixed assets Rs m85,016129,876 65.5%   
Share capital Rs m846904 93.6%   
"Free" reserves Rs m45,376134,866 33.6%   
Net worth Rs m46,222135,771 34.0%   
Long term debt Rs m41,11564,245 64.0%   
Total assets Rs m142,432263,054 54.1%  
Interest coverage x4.010.8 37.1%   
Debt to equity ratio x0.90.5 188.0%  
Sales to assets ratio x0.40.6 70.1%   
Return on assets %6.91.7 399.9%  
Return on equity %14.71.9 792.8%  
Return on capital %14.23.7 381.5%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m14,58053,141 27.4%   
Fx outflow Rs m3,60019,335 18.6%   
Net fx Rs m10,98033,807 32.5%   
CASH FLOW
From Operations Rs m8,94217,512 51.1%  
From Investments Rs m-47,070-14,073 334.5%  
From Financial Activity Rs m34,174-14,921 -229.0%  
Net Cashflow Rs m-3,655-11,482 31.8%  

Share Holding

Indian Promoters % 71.5 46.6 153.4%  
Foreign collaborators % 0.0 0.2 -  
Indian inst/Mut Fund % 7.0 11.3 62.1%  
FIIs % 12.6 31.9 39.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.8 10.1 87.1%  
Shareholders   26,511 98,259 27.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare TORRENT PHARMA With:   UNICHEM LAB  AUROBINDO PHARMA  IPCA LABS  GLENMARK PHARMA  SUN PHARMA  

Compare TORRENT PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Marginally Higher; Realty and IT Stocks Witness Buying(Closing)

Indian share markets witnessed volatility during closing hours and ended their day marginally higher. Gains were largely seen in the realty sector and IT sector.

Related Views on News

LUPIN LTD Announces Quarterly Results (3QFY19); Net Profit Down 149.7% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, LUPIN LTD has posted a net profit of Rs 2 bn (down 149.7% YoY). Sales on the other hand came in at Rs 45 bn (up 78.0% YoY). Read on for a complete analysis of LUPIN LTD's quarterly results.

TORRENT PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 324.1% (Quarterly Result Update)

Jan 31, 2019 | Updated on Jan 31, 2019

For the quarter ended December 2018, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 324.1% YoY). Sales on the other hand came in at Rs 21 bn (up 38.9% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

LUPIN LTD Announces Quarterly Results (2QFY19); Net Profit Down 31.1% (Quarterly Result Update)

Nov 6, 2018 | Updated on Nov 6, 2018

For the quarter ended September 2018, LUPIN LTD has posted a net profit of Rs 3 bn (down 31.1% YoY). Sales on the other hand came in at Rs 40 bn (up 53.1% YoY). Read on for a complete analysis of LUPIN LTD's quarterly results.

TORRENT PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 12.3% (Quarterly Result Update)

Nov 5, 2018 | Updated on Nov 5, 2018

For the quarter ended September 2018, TORRENT PHARMA has posted a net profit of Rs 2 bn (down 12.3% YoY). Sales on the other hand came in at Rs 19 bn (up 32.5% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

LUPIN LTD 2017-18 Annual Report Analysis (Annual Result Update)

Aug 16, 2018 | Updated on Aug 16, 2018

Here's an analysis of the annual report of LUPIN LTD for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of LUPIN LTD. Also includes updates on the valuation of LUPIN LTD.

More Views on News

Most Popular

Are You Ready for the Big Nifty Move in the March Expiry?(Profit Hunter)

Mar 8, 2019

History suggests the Nifty could make a big move in March. Are you prepared to benefit from this opportunity?

5 Fundamentally Strong Stocks to Pick for Trading Today(Profit Hunter)

Mar 15, 2019

5 fundamentally strong stocks one could buy to trade in this market right now. Make sure you grab the chance this strongly rallying market offers.

Elections Don't Matter!(The Honest Truth)

Mar 13, 2019

Ajit Dayal shows us why from the point of view of the Indian economy, elections don't matter.

Two Growth Stocks that Doubled in a Little Over 12 Months!(The 5 Minute Wrapup)

Mar 13, 2019

The elements that fueled profit growth for these two companies led to a surge in their stock prices.

This is Why You Need to Buy Small Cap Stocks Now(The 5 Minute Wrapup)

Mar 15, 2019

Did you just miss the smallcap rally? Or is there still time to catch up? Read on for answers and more...

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

TORRENT PHARMA SHARE PRICE


Mar 20, 2019 (Close)

TRACK TORRENT PHARMA

  • Track your investment in TORRENT PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TORRENT PHARMA

TORRENT PHARMA 5-YR ANALYSIS

COMPARE TORRENT PHARMA WITH

MARKET STATS